Aprogen Subsidiary Issues 50.8 Billion Won Convertible Bonds to Repay Affiliate Debt - Concerns Over Severe Dilution and Stock Price Decline
Aprogen's subsidiary Aprogen Biologics has decided to issue 50.8 billion won in private convertible bonds to affiliate Aptochrome. The CBs will be paid by offsetting Aptochrome's loan receivables from Aprogen Biologics, and all proceeds will be used to repay borrowings from Aptochrome.
The conversion price is set at 3,778 won, and upon conversion, 13.44 million new shares will be issued, representing 93.3% of the subsidiary's current outstanding shares. Including existing outstanding CBs, the potential dilution ratio reaches 262.78%, severely impairing existing shareholder value.
The conversion price can be adjusted down to a minimum of 2,645 won if the stock price falls, creating further dilution risk. The funding is used for debt repayment to a related party, not for growth, and the counterparty being an affiliate of the largest shareholder raises governance concerns. No shareholder return measures have been announced.
[AI Summary]Aprogen's subsidiary issuing large-scale convertible bonds severely dilutes existing shareholder value, and the use of proceeds for related-party debt repayment is negative. The related-party transaction adds transparency risks. Short-term stock price decline is expected.
KOSPI Filing Information
[Correction of Description] Report On Major Matters (Decision On Issuance Of Convertible Bonds) (Major Management Matters Of Subsidiary)